iron

all catalysts(1)

News(10)

• Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
  Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collabora…
  fiercebiotech · 12d ago
• Kairon Health raises $5M to use data to make patients healthier
  A startup that helps value-based healthcare practices turn patient data into a to-do list for staff has raised new funding, Endpoints News learned exclusively. Kairon Health pulls together patient…
  endpoints · 19d ago
• A booming business on Wall Street would love more biotechs to quietly die
  Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
  biopharma_dive · 24d ago
• Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill
  “Nothing in the recent reporting about John Fetterman is medically surprising,” write Michael P.H. Stanley and Isaiah Kletenik.
  stat · 24d ago
• Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
  Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
  biopharma_dive · 1mo ago
• FDA OKs Takeda, Protagonist drug for rare blood cancer
  The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
  biopharma_dive · 1mo ago
• Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
  The approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…
  biospace · 1mo ago
• FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
  The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood c…
  fda_press · 1mo ago
• Amgen, academic centers weigh new FDA pilot to speed early drug trials
  To better combat China and Australia's dominance in expediting early-phase trials, the FDA and stakeholders are ironing out the details of a pilot program to accelerate first-in-human trials. Amgen…
  endpoints · 1mo ago
• Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
  The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
  biospace · 1mo ago